Loading viewer...
conference
Format: PDF conference
Tonix Pharmaceuticals presented its clinical-stage fibromyalgia treatment TNX-102 SL, highlighting two positive Phase 3 trials with NDA filing expected in H2 2024 and FDA approval anticipated in H2 2025. The company is a CNS-focused biopharma with marketed migraine therapies and a pipeline including a biologic cocaine antidote with FDA Breakthrough Therapy Designation.
investor_presentation
48 Pages
conference
14 Pages
Washington State Department of Transportation (WSDOT)
Neumora Therapeutics 2024 J.P. Morgan Healthcare Conference
conferenceconference
28 Pages
Neumora Therapeutics, Inc.
AAVAS Financiers 2018 Banking Financial Services Conference
conferenceconference
1 Pages
AAVAS Financiers Limited